Radiographic results from a long-term multicenter trial of etanercept (ENBREL®) in patients with ankylosing spondylitis

被引：0
|
作者：
van der Horst-Bruinsma, I.
Wanders, A.
van der Heijde, D.
Fatenejad, S.
机构：
[1] AZ Vrije Univ, Reumatol Afdeling, Amsterdam, Netherlands
[2] Univ Hosp, Dept Rheumatol, Maastricht, Antilles, Netherlands
[3] Wyeth, Collegeville, PA USA
来源：
RHEUMATOLOGY | 2006年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：I5 / I5
页数：1
相关论文
共 50 条
  • [21] Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice
    Arends, S.
    Brouwer, E.
    Efde, M.
    van der Veer, E.
    Bootsma, H.
    Wink, F.
    Spoorenberg, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : 61 - 68
  • [22] Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
    Webers, Casper
    Essers, Ivette
    Ramiro, Sofia
    StolwijK, Carmen
    Landewe, Robert
    van der Heijde, Desiree
    van den Bosch, Filip
    Dougados, Maxime
    van Tubergen, Astrid
    RHEUMATOLOGY, 2016, 55 (03) : 419 - 428
  • [23] LONG-TERM OUTCOME OF PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WITH ETANERCEPT - SUSTAINED EFFICACY AND SAFETY AFTER 7 YEARS
    Baraliakos, X.
    Haibel, H.
    Fritz, C.
    Listing, J.
    Heldmann, F.
    Braun, J.
    Sieper, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 638 - 638
  • [24] GENDER-ATTRIBUTABLE DIFFERENCES IN OUTCOME OF ANKYLOSING SPONDYLITIS: LONG-TERM RESULTS FROM THE OUTCOME IN ANKYLOSING SPONDYLITIS INTERNATIONAL STUDY
    Webers, C.
    Essers, I.
    Ramiro, S.
    Stolwijk, C.
    Landewe, R.
    van der Heijde, D.
    van den Bosch, F.
    Dougados, M.
    van Tubergen, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 744 - 745
  • [25] Long term efficacy and safety results and patient reported outcomes in patients with ankylosing spondylitis treated with etanercept for 4 years
    Dijkmans, B. A. C.
    Sieper, J.
    van der Linden, S.
    Martin-Mola, E.
    Leirisalo-Repo, M.
    Singh, A.
    Freundlich, B.
    Koenig, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 395 - 395
  • [26] Long-term use of ENBREL® (Etanercept) in patients with DMARD-refractory rheumatoid arthritis
    Baumgartner, SW
    Moreland, LW
    Cohen, SB
    Schiff, MH
    Tindall, EA
    Burge, DJ
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 104 - 104
  • [27] COMPARISON OF LONG-TERM DRUG SURVIVAL OUTCOME WITH ETANERCEPT TREATMENT AND ADALIMUMAB TREATMENT OF ANKYLOSING SPONDYLITIS
    Ruwaard, J.
    I'Ami, M.
    Marsman, A.
    Kneepkens, E.
    van der Horst-Bruinsma, I. E.
    van Denderen, C.
    Nurmohamed, M. T.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 813 - 813
  • [28] The long-term natural course of radiographic progression in ankylosing spondylitis evaluation of a large as cohort
    Baraliakos, X.
    Listing, J.
    van der Recke, A.
    Braun, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 389 - 389
  • [29] Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
    van der Heijde, D.
    Schiff, M. H.
    Sieper, J.
    Kivitz, A. J.
    Wong, R. L.
    Kupper, H.
    Dijkmans, B. A. C.
    Mease, P. J.
    Davis, J. C., Jr.
    ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) : 922 - 929
  • [30] Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study.
    Webers, Casper
    Essers, Ivette
    Ramiro, Sofia
    Stolwijk, Carmen
    Landewe, Robert
    van der Heijde, Desiree
    van den Bosch, Filip
    Dougados, Maxime
    van Tubergen, Astrid
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1137 - S1137
12345